A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
A phase 2 trial of APG-115 in hodgkin lymphoma, run by Ascentage Pharma Group Inc., now recruiting.
Overview
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL is a phase 2 interventional study registered as NCT04496349 by Ascentage Pharma Group Inc., with 78 participants planned, started 2021-07-12 and due to reach its primary completion in 2026-05-31. Interventions recorded: APG-115 and APG-2575.
Similar pages
not linked directly; found by shared links- TrialStudy of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
Shares Ascentage Pharma and the tag pipeline.
- TrialAPG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors
Shares Ascentage Pharma and the tag pipeline.
- TrialA Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia
Shares Ascentage Pharma and the tag pipeline.
- TrialAPG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
Shares Ascentage Pharma and the tag pipeline.
- TrialStudy of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
Shares Ascentage Pharma and the tag pipeline.
- TrialT-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Shares Hodgkin lymphoma and the tag pipeline.
- TreatmentAT101
Shares Hodgkin lymphoma and the tag pipeline.
- TreatmentEnglumafusp alfa
Shares Hodgkin lymphoma and the tag pipeline.